Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol. The study evaluates if selecting the starting dose based on baseline and target LDL-C cholesterol would provide better results (ie proportion of subjects resching target)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Atorvastatin (Lipitor) | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of subjects achieving a LDL-C target of < 100 mg/dL (2.6 mmol/L) after 12 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of subjects achieving: | ||
| LDL-C target <100 mg/dL (<2.6 mmol/L) after 6 weeks of treatment. | ||
| Total cholesterol (TC)/HDL-C ratio target (<4.0) after 6 and 12 weeks of treatment. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Mississauga | Ontario | Cameroon | |||
| Pfizer Investigational Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21610204 | Derived | Gupta M, Martineau P, Tran T, Despres JP, Gaw A, de Teresa E, Farsang C, Gensini GF, Leiter LA, Blanco-Colio LM, Egido J, Langer A; ACTFAST investigators. Low-density lipoprotein cholesterol and high-sensitivity C-reactive protein lowering with atorvastatin in patients of South Asian compared with European origin: insights from the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. J Clin Pharmacol. 2012 Jun;52(6):850-8. doi: 10.1177/0091270011407196. Epub 2011 May 24. | |
| 19217176 |
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Either the LDL-C <100mg/dL (<2.6 mmol/L) or TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment. |
| Both the LDL-C <100mg/dL (<2.6 mmol/L) and TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment. |
| LDL-C <100mg/dL (<2.6 mmol/L) or TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment by LDL-C strata. |
| LDL-C target (<100 mg/dL) by primary inclusion diagnosis (CHD, CHD-equivalent, diabetes or 10-year CHD risk-equivalent >20%). |
| The mean percent change in LDL-C, high density lipoprotein cholesterol (HDL-C),TC/HDL-C ratio, non HDL-C (in subjects with triglycerides [TG] ≥200 mg/dL or 2.3 mmol/L), TC and TG from baseline to 6 and 12 weeks of treatment. |
| Change from baseline in apolipoprotein-B (Apo-B) and change from baseline in glycosylated hemoglobin (HbA1c) was assessed at 12 weeks. |
| Calgary |
| Alberta |
| Canada |
| Pfizer Investigational Site | Edmonton | Alberta | Canada |
| Pfizer Investigational Site | Medicine Hat | Alberta | Canada |
| Pfizer Investigational Site | Red Deer | Alberta | Canada |
| Pfizer Investigational Site | Campbell River | British Columbia | Canada |
| Pfizer Investigational Site | Maple Ridge | British Columbia | Canada |
| Pfizer Investigational Site | Nanaimo | British Columbia | Canada |
| Pfizer Investigational Site | New Westminster | British Columbia | Canada |
| Pfizer Investigational Site | Richmond | British Columbia | Canada |
| Pfizer Investigational Site | Surrey | British Columbia | Canada |
| Pfizer Investigational Site | Vancouver | British Columbia | Canada |
| Pfizer Investigational Site | Vernon | British Columbia | Canada |
| Pfizer Investigational Site | Victoria | British Columbia | Canada |
| Pfizer Investigational Site | Brandon | Manitoba | Canada |
| Pfizer Investigational Site | Winnipeg | Manitoba | Canada |
| Pfizer Investigational Site | Ajax | Ontario | Canada |
| Pfizer Investigational Site | Brampton | Ontario | Canada |
| Pfizer Investigational Site | Burlington | Ontario | Canada |
| Pfizer Investigational Site | Cambridge | Ontario | Canada |
| Pfizer Investigational Site | Cornwall | Ontario | Canada |
| Pfizer Investigational Site | Etobicoke | Ontario | Canada |
| Pfizer Investigational Site | Mississauga | Ontario | Canada |
| Pfizer Investigational Site | Niagara Falls | Ontario | Canada |
| Pfizer Investigational Site | North YORK | Ontario | Canada |
| Pfizer Investigational Site | Orillia | Ontario | Canada |
| Pfizer Investigational Site | Oshawa | Ontario | Canada |
| Pfizer Investigational Site | Rexdale | Ontario | Canada |
| Pfizer Investigational Site | Sarnia | Ontario | Canada |
| Pfizer Investigational Site | Scarborough Village | Ontario | Canada |
| Pfizer Investigational Site | Simcoe | Ontario | Canada |
| Pfizer Investigational Site | Thunder Bay | Ontario | Canada |
| Pfizer Investigational Site | Toronto | Ontario | Canada |
| Pfizer Investigational Site | Weston | Ontario | Canada |
| Pfizer Investigational Site | Whitby | Ontario | Canada |
| Pfizer Investigational Site | Willowdale | Ontario | Canada |
| Pfizer Investigational Site | Chicoutimi | Quebec | Canada |
| Pfizer Investigational Site | Cowansville | Quebec | Canada |
| Pfizer Investigational Site | Drummondville | Quebec | Canada |
| Pfizer Investigational Site | Joliette | Quebec | Canada |
| Pfizer Investigational Site | Laval | Quebec | Canada |
| Pfizer Investigational Site | Lévis | Quebec | Canada |
| Pfizer Investigational Site | Maria | Quebec | Canada |
| Pfizer Investigational Site | Montreal | Quebec | Canada |
| Pfizer Investigational Site | Newport | Quebec | Canada |
| Pfizer Investigational Site | Pointe-Claire | Quebec | Canada |
| Pfizer Investigational Site | Repentigny | Quebec | Canada |
| Pfizer Investigational Site | Saint-Hyacinthe | Quebec | Canada |
| Pfizer Investigational Site | Saint-Lambert | Quebec | Canada |
| Pfizer Investigational Site | Sainte-Foy | Quebec | Canada |
| Pfizer Investigational Site | Sherbrooke | Quebec | Canada |
| Pfizer Investigational Site | St-georges (beauce) | Quebec | Canada |
| Pfizer Investigational Site | Thetford-Mines | Quebec | Canada |
| Pfizer Investigational Site | Vaudreuil | Quebec | Canada |
| Pfizer Investigational Site | Saskatoon | Saskatchewan | Canada |
| Pfizer Investigational Site | Québec | Canada |
| Pfizer Investigational Site | Tricase | (LE) | Italy |
| Pfizer Investigational Site | Vimercate | (MI) | Italy |
| Pfizer Investigational Site | Somma Lombardo | (VA) | Italy |
| Pfizer Investigational Site | Asti | Italy |
| Pfizer Investigational Site | Bari | Italy |
| Pfizer Investigational Site | Belluno | Italy |
| Pfizer Investigational Site | Bologna | Italy |
| Pfizer Investigational Site | Bolzano | Italy |
| Pfizer Investigational Site | Catania | Italy |
| Pfizer Investigational Site | Chieti | Italy |
| Pfizer Investigational Site | Ferrara | Italy |
| Pfizer Investigational Site | Florence | Italy |
| Pfizer Investigational Site | Foggia | Italy |
| Pfizer Investigational Site | Grosseto | Italy |
| Pfizer Investigational Site | Naples | Italy |
| Pfizer Investigational Site | Novara | Italy |
| Pfizer Investigational Site | Palermo | Italy |
| Pfizer Investigational Site | Perugia | Italy |
| Pfizer Investigational Site | Potenza | Italy |
| Pfizer Investigational Site | Prato | Italy |
| Pfizer Investigational Site | Roma | Italy |
| Pfizer Investigational Site | Salerno | Italy |
| Pfizer Investigational Site | San Donato Milanese | Italy |
| Pfizer Investigational Site | Sassari | Italy |
| Pfizer Investigational Site | Savona | Italy |
| Pfizer Investigational Site | Siena | Italy |
| Pfizer Investigational Site | Torino | Italy |
| Pfizer Investigational Site | Venezia | Italy |
| Pfizer Investigational Site | L'Hospitalet de Llobregat | Barcelona | Spain |
| Pfizer Investigational Site | Girona | Catalonia | Spain |
| Pfizer Investigational Site | Galdakao | Vizcaya | Spain |
| Pfizer Investigational Site | Ávila | Spain |
| Pfizer Investigational Site | Barcelona | Spain |
| Pfizer Investigational Site | Granada | Spain |
| Pfizer Investigational Site | Huelva | Spain |
| Pfizer Investigational Site | Jerez de la Frontera | Spain |
| Pfizer Investigational Site | Madrid | Spain |
| Pfizer Investigational Site | Marbella | Spain |
| Pfizer Investigational Site | Seville | Spain |
| Pfizer Investigational Site | Tarragona | Spain |
| Pfizer Investigational Site | Valencia | Spain |
| Pfizer Investigational Site | Newtonabbey | Belfast | United Kingdom |
| Pfizer Investigational Site | Aylesbury | Buckinghamshire | United Kingdom |
| Pfizer Investigational Site | Ely | Cambs | United Kingdom |
| Pfizer Investigational Site | Peterborough | Cambs | United Kingdom |
| Pfizer Investigational Site | Newtonabbey | CO Antrim | United Kingdom |
| Pfizer Investigational Site | Hastings | EAST Sussex | United Kingdom |
| Pfizer Investigational Site | High Valleyfield | FIFE | United Kingdom |
| Pfizer Investigational Site | Rutherglen | Glasgow | United Kingdom |
| Pfizer Investigational Site | Leslie, FIFE | Glenrotheshire | United Kingdom |
| Pfizer Investigational Site | Sunbury-on-Thames | Middlesex | United Kingdom |
| Pfizer Investigational Site | Frome | Somerset | United Kingdom |
| Pfizer Investigational Site | Barry | South Glamorgan | United Kingdom |
| Pfizer Investigational Site | Doncaster | South Yorkshire | United Kingdom |
| Pfizer Investigational Site | Stairfoot, Barnsley | South Yorkshire | United Kingdom |
| Pfizer Investigational Site | Addlestone | Surrey | United Kingdom |
| Pfizer Investigational Site | East Horsley | Surrey | United Kingdom |
| Pfizer Investigational Site | Atherstone | Warks | United Kingdom |
| Pfizer Investigational Site | Balsall Common | WEST Midlands | United Kingdom |
| Pfizer Investigational Site | Pound Hill, Crawley | WEST Sussex | United Kingdom |
| Pfizer Investigational Site | Trowbridge | Wiltshire | United Kingdom |
| Pfizer Investigational Site | Chippenham | Wilts | United Kingdom |
| Pfizer Investigational Site | Sheffield | Yorkshire | United Kingdom |
| Pfizer Investigational Site | Bath | United Kingdom |
| Pfizer Investigational Site |
| Derived |
| Gensini GF, Gori AM, Dilaghi B, Rostagno C, Gaw A, Blanco-Colio LM, de Teresa E, Egido J, Farsang C, Leiter LA, Martineau P, Nozza A, Langer A; Achieve Cholesterol Targets Fast withAtorvastatin Stratified Titration Investigators. Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. Int J Cardiol. 2010 Jul 23;142(3):257-64. doi: 10.1016/j.ijcard.2008.12.213. Epub 2009 Feb 12. |
| ID | Term |
|---|---|
| D003324 | Coronary Artery Disease |
| D003924 | Diabetes Mellitus, Type 2 |
| D020521 | Stroke |
| D050171 | Dyslipidemias |
| D016491 | Peripheral Vascular Diseases |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D052439 | Lipid Metabolism Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069059 | Atorvastatin |
| ID | Term |
|---|---|
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006538 | Heptanoic Acids |
| D005227 | Fatty Acids |
| D008055 | Lipids |
Not provided
Not provided